Effects of sodium butyrate on aversive memory in rats submitted to sepsis

Neuroscience Letters

Volumn 595, Issue , 2015, Pages 134-138

  Steckert, Amanda V ^a   Comim, Clarissa M ^a   Igna, Dhébora M Dall ^a   Dominguini, Diogo ^a   Mendonça, Bruna P ^a   Ornell, Felipe ^a   Colpo, Gabriela D ^c   Gubert, Carolina ^c   Kapczinski, Flávio ^c   Barichello, Tatiana ^a,b   Quevedo, João ^a,b   Dal Pizzol, Felipe ^a  

^a UNIVERSITY OF SOUTHERN SANTA CATARINA   (Brazil)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Brain; Histone deacetylase; Memory; Sepsis; Sodium butyrate

Indexed keywords

BUTYRIC ACID; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ARTIFICIAL CEREBROSPINAL FLUID; AVERSIVE MEMORY; AVOIDANCE BEHAVIOR; BRAIN CORTEX; BRAIN TISSUE; BRAIN VENTRICLE; CECAL LIGATION PERFORATION; CECUM; CEREBROSPINAL FLUID; CLINICAL EVALUATION; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; DRUG INFUSION; EPIGENETICS; HIPPOCAMPUS; HISTONE MODIFICATION; INTESTINE INJURY; LIGATION; MALE; MEMORY; MEMORY DISORDER; MICROINJECTION; NONHUMAN; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN DETERMINATION; RAT; SEPSIS; STEREOTAXIC SURGERY; TASK PERFORMANCE; ANIMAL; COMPLICATION; DRUG EFFECTS; ENZYMOLOGY; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MEMORY DISORDERS; METABOLISM; WISTAR RAT;

ANIMALS; BUTYRIC ACID; HIPPOCAMPUS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; INJECTIONS, INTRAVENTRICULAR; MALE; MEMORY DISORDERS; MICROINJECTIONS; PREFRONTAL CORTEX; RATS, WISTAR; SEPSIS;

EID: 84927943681     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2015.04.019     Document Type: Article

References (43)

1. Urnov F.D., Wolffe A.P. Chromatin remodeling and transcriptional activation: the cast (in order of appearance). Oncogene 2001, 20:2991.
2. Wu X., Chen P.S., Dallas S., Wilson B., Block M.L., Wang C.C., Kinyamu H., Lu N., Gao X., Leng Y., Chuang D.M., Zhang W., Lu R.B., Hong J.S. Histone deacetylase inhibitors upregulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons. Int. J. Neuropsychopharmacol. 2008, 11:1123-1134.
3. Workman J.L., Kingston R.E. Alteration of nucleosome structure as a mechanism of transcriptional regulation. Annu. Rev. Biochem. 1998, 67:545-579.
4. Kim M.S., Kwon H.J., Lee Y.M., Baek J.H., Jang J.E., Lee S.K., Chung H.Y., Kim C.W., Kin K.W. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat. Med. 2001, 7:437.
5. Machado-Vieira M., Ibrahim L., Zarate C.A. Histone deacetylases and mood disorders: epigenetic programming in gene-environment interactions. CNS Neurosci. Ther. 2011, 17(6):699-704.
6. MacDonald J.L., Roskams A.J. Epigenetic regulation of nervous system development by DNA methylation and histone deacetylation. Prog. Neurobiol. 2009, 88:170-183.
7. Zhang T.Y., Meaney M.J. Epigenetics and the environmental regulation of the genome and its function. Annu. Rev. Psychol. 2010, 61:439-466.
8. Pan L.N., Lu J., Huang B. HDAC inhibitors: a potential new category of anti-tumor agents. Cell Mol. Immunol. 2007, 4:337-343.
9. Ciarlo E., Athina S., Roger T. Epigenetics in sepsis: targeting histone deacetylase. Int. J. Antimicrob. Agents 2013, 42S:S8-S12.
10. Kumar S., Leaper D.J. Basic science of sepsis. Surgery 2005, 23:272-277.
11. Li Y., Alam H.B. Modulation of acetylation: creating a pro-survival and anti-inflammatory phenotype in lethal hemorrhagic and septic shock. J. Biomed. Biotechnol. 2011, 2011:523481.
12. Leoni F., Fossati G., Lewis E.C., Lee J.K., Pagani P., Modena D., Moras M.L., Pozzi P., Reznikov L.L., Siegmund B., Fantuzzi G., Dinarello C.A., Mascagni P. The histone deacetylase inhibitor ITF2357 reduces production of proinflammatory cytokines in vitro and systemic inflammation in vivo. Mol. Med. 2005, 11(1-12):1-15.
13. Cao W., Bao C., Padalko E., Lowenstein C.J. Acetylation of mitogen-activated protein kinase phosphatase-1 inhibits toll-like receptor signaling. J. Exp. Med. 2008, 205(6):1491-1503.
14. Barichello T., Fortunato J.J., Vitali A.M., Feier G., Reinke A., Moreira J.F.C., Quevedo J., Pizzol F.D. Oxidative variables in the rat brain after sepsis induced by cecal ligation and perforation. Crit. Care Med. 2006, 34:886-889.
15. Comim C.M., Cassol-Jr O.J., Constantino L.S., Felisberto F., Petronilho F., Rezin G.T., Scaini G., Daufenbach J.F., Streck E.L., Quevedo J., Dal-Pizzol F. Alterations in inflammatory mediators, oxidative stress parameters and energetic metabolism in the brain of sepsis survivors rats. Neurochem. Res. 2011, 36:304-311.
16. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1986, Academic Press, San Diego.
17. Wang D., Wang Z., Tian B., Li X., Li S., Tian Y. Two hour exposure to sodium butyrate sensitizes bladder cancer to anticancer drugs. Int. J. Urol. 2008, 15:435-441.
18. Arent C.O., Valvassori S.S., Fries G.R., Stertz L., Ferreira C.L., Lopes-Borges J., Mariot E., Varela R.B., Ornell F., Kapczinski F., Andersen M.L., Quevedo J. Neuroanatomical profile of antimaniac effects of histone deacetylases inhibitors. Mol. Neurobiol. 2011, 43:207-214.
19. Comim C.M., Cassol O.J., Constantino L.C., Petronilho F., Constantino L.S., Stertz L., Kapczinski F., Barichello T., Quevedo J., Dal-Pizzol F. Depressive-like parameters in sepsis survivor rats. Neurotox. Res. 2010, 17(3):279-286.
20. Ritter C., Andrades M.E., Reinke A., Menna-Barreto S., Moreira J.C.F., Dal-Pizzol F. Treatment with N-acetylcysteine plus deferoxamine protects rats against oxidative stress and improves survival in sepsis. Crit. Care Med. 2004, 32:342-349.
21. Steckert A.V., Comim C.M., Mina F., Mendonça B.P., Dominguini D., Ferreira G.K., Carvalho-Silva M., Vieira J.S., Streck E.L., Quevedo J., Dal-Pizzol F. Late brain alterations in sepsis-survivor rats. Synapse 2013, 67(11):786-793.
22. Roesler R., Vianna M.R., de-Paris F., Quevedo J. Memory-enhancing treatments do not reverse the impairment of inhibitory avoidance retention induced by NMDA receptor blockade. Neurobiol. Learn. Mem. 1999, 72:252-258.
23. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193:265-267.
24. Rutten B.P., Mill J. Epigenetic mediation of environmental influences in major psychotic disorders. Schizophrenia Bull. 2009, 35:1045-1056.
25. Bierne H., Hamon M., Cossart P. Epigenetics and bacterial infections. Cold Spring Harbor Perspect. Med. 2012, 2:a010272.
26. Young G.B., Bolton C.F., Austin T.W., Archibald Y.M., Gonder J., Wells G.A. The encephalopathy associated with septic illness. Clin. Invest. Med. 1990, 13:297-304.
27. Dal-Pizzol F., Ritter C., Cassol-Jr O.J., Rezin G.T., Petronilho F., Zugno A.I., Quevedo J., Streck E.L. Oxidative mechanisms of brain dysfunction during sepsis. Neurochem. Res. 2010, 35:1-12.
28. Lewin G.R., Barde Y.A. Physiology of the neurotrophins. Annu. Rev. Neurosci. 1996, 9:289-317.
29. Duman R.S., Monteggia L.M. A neurotrophic model for stress-related mood disorders. Biol. Psychiatry 2006, 59(12):1116-1127.
30. Zeng Y., Tan M., Kohyama J., Sneddon M., Watson J.B., Sun Y.E., Xie C.W. Epigenetic enhancement of BDNF signaling rescues synaptic plasticity in aging. J. Neurosci. 2011, 31:17800-17810.
31. Sui L., Wang Y., Ju L.H., Chen M. Epigenetic regulation of reelin and brainderived neurotrophic factor genes in long-term potentiation in rat medial prefrontal córtex. Neurobiol. Learn. Mem. 2012, 97:425-440.
32. Alarcon J.M., Malleret G., Touzani K., Vronskaya S., Ishii S., Kandel E.R., Barco A. Chromatin acetylation, memory and LTP are impaired in CBP+/- mice: a model for the cognitive deficit in Rubinstein-Taybi syndrome and its amelioration. Neuron 2004, 42:947-959.
33. Korzus E., Rosenfeld M.G., Mayford M. CBP histone acetyltransferase activity is a critical component of memory consolidation. Neuron 2004, 42:961-972.
34. Fischer A., Sananbenesi F., Mungenast A., Tsai L.H. Targeting the correct HDAC(s) to treat cognitive disorders. Trends Pharmacol. Sci. 2010, 31:605-617.
35. Graff J., Tsai L.H. Histone acetylation: molecular mnemonics on the chromatin. Nat. Rev. Neurosci. 2013, 14:97-111.
36. Yasuda S., Liang M.H., Marinova Z., Yahyavi A., Chuang D.M. The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Mol. Psychiatry 2009, 14:51-59.
37. Wu J., Dong L., Zhang M., Jia M., Zhang G., Qiu L., Ji M., Yang J. Class I histone deacetylase inhibitor valproic acid reverses cognitive deficits in a mouse model of septic encephalopathy. Neurochem. Res. 2013, 38(11):2440-2449.
38. Dash P.K., Orsi S.A., Zhang M., Grill R.J., Pati S., Zhao J., Moore A.N. Valproate administered after traumatic brain injury provides neuroprotection and improves cognitive function in rats. PLoS One 2010, 5(6):e11383.
39. Xuan A., Long D., Li J., Ji W., Hong L., Zhang M. Neuroprotective effects of valproic acid following transient global ischemia rats. Life Sci. 2012, 90(11-12):463-468.
40. Chen P.S., Wang C.C., Bortner C.D., Peng G.S., Wu X., Pang H., Lu R.B., Gean P.W., Chuang D.M., Hong J.S. Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity. Neuroscience 2007, 149:203-212.
41. Fang J., Lian Y., Xie K., Cai S., Wen P. Epigenetic modulation of neuronal apoptosis and cognitive functions in sepsis-associated encephalopathy. Neurol. Sci. 2014, 35(2):283-288.
42. Sonnewald U., Hertz L., Schousboe A. Mitochondrial heterogeneity in the brain at the cellular level. J. Cereb. Blood Flow Metab. 1998, 8:231-237.
43. Fukumoto T., Morinobu S., Okamoto Y., Kagaya A., Yamawaki S. Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacology (Berl.) 2001, 158:100-106.